Lung Cancer Screening: Do You Need It?

If you are at a high risk for lung cancer, experts recommend that you get screened yearly. But only a very small number of cancers are found through screening, and the process itself poses some risks. So should you still get checked?

The American Cancer Society, American Lung Association and the U.S. Preventive Services Task Force say yes — if you’re older and are (or were) a longtime smoker.

Peter Mazzone, MD, MPH, Director of the Lung Cancer Screening Program for Cleveland Clinic’s Respiratory Institute, helps us take a closer look at what you need to know about screening.

Q: What patients do doctors typically refer for screening?

A: Your doctor likely will refer you for screening if you fall into these categories:

  • You are between age 55 and 77
  • You have smoked at least 30 pack years of cigarettes (figured by multiplying the number of packs you smoked each day by the amount of time you smoked: 30 pack years is one pack a day for 30 years or two packs a day for 15 years)
  • You have been a smoker in the past 15 years

It’s also important that you’re healthy enough to benefit from finding and treating early-stage lung cancer.

If someone comes to us in a wheelchair wearing oxygen and couldn’t tolerate treatment, they typically aren’t eligible for screening. However, there are nearly 9 million Americans who are at high risk and should receive screening.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oncimmune Holdings PLC

    More articles like this

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous

    Oncimmune signs go-to-market partnership with Synexa Life Sciences

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker

    Oncimmune signs new commercial contract with Verily Life Sciences 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients

    Oncimmune Holdings Notice of half year results

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune

    Oncimmune achieves FY2021 revenue of £3.7 million

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its audited results for the year ended 31 May 2021 and provides an update on recent progress and the outlook for the current financial year.

    Oncimmune to evaluate the profile of patients using ImmunoINSIGHTS

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The